Thomas Okarma

Internationally recognized biotechnology chief executive officer, board member, clinician-scientist, and entrepreneur with demonstrated management expertise spanning basic research, clinical medicine, product development, regulatory affairs, GMP manufacturing, clinical operations, corporate partnering, and corporate finance.

Transformed two US biotechnology companies from early stage science through product development to Phase 2 and Phase 3 pivotal clinical trials.

Acknowledged as a preeminent industrial pioneer and spokesman for telomerase-targeted cancer treatments, hESC-based cell therapy, and regenerative medicine.